Synergistic drug homing for glioblastoma: Integrating biomimetic nanocarriers with MR-guided focused ultrasound across the blood-brain barrier
Source abstract
Abstract
Background The blood–brain barrier (BBB) and its pathological counterpart, the heterogeneous blood–tumor barrier (BTB), remain major obstacles to effective chemotherapy for glioblastoma multiforme (GBM). Although bioengineered nanocarriers exploiting receptor-mediated transcytosis have shown promise for targeted drug delivery, their efficacy is constrained by receptor saturation, endogenous ligand competition, and endosomal sequestration. Magnetic resonance-guided focused ultrasound (MRgFUS) enables transient and localized BBB opening but lacks intrinsic tumor selectivity. Objective This review aimed to answer the following PICO question: In patients or animal models with GBM (Population ) , does the combination of systemically administered nanocarriers with MRgFUS (Intervention), compared with systemic nanocarriers or FUS alone (Comparison), improve BBB penetration, drug accumulation, or survival outcomes (Outcome)? Methods This systematic review was conducted in accordance with the PRISMA 2020 guidelines. The search strategy combined MeSH and free-text terms: ('blood-brain barrier’ OR BBB) AND ('glioblastoma’ OR GBM) AND ('nanoparticle ’ OR ‘nanocarrier ’ OR ‘exosome ’) AND ('focused ultrasound’ OR 'MRgFUS' OR ‘microbubble ’) in PubMed, Web of Science, and Scopus for articles published January 2018–December 2025. Eligible studies included preclinical or clinical investigations reporting the use of systemically administered nanocarriers combined with focused ultrasound for GBM therapy. Two reviewers independently performed study selection and data extraction . Effect measures extracted included fold changes in brain accumulation (%ID/g or AUC), median survival differences, and tumor volume reductions. Owing to substantial heterogeneity in study designs, nanoparticle platforms, animal models, and outcome measures, a narrative synthesis was performed. Methodological quality was assessed qualitatively; confidence in the synthesized evidence was evaluated using a GRADE-informed approach considering study limitations, inconsistency, indirectness, imprecision, and publication bias. A review protocol was not prospectively registered. Results Of 1247 records identified, 83 studies met the inclusion criteria (80 preclinical, 3 clinical). The evidence supports a Synergistic Drug Homing (SDH) paradigm integrating biomimetic nanocarriers with spatiotemporally controlled acoustic modulation of BBB permeability. Across representative studies, MRgFUS increased intraparenchymal drug accumulation by approximately 2- to 7.7-fold compared with systemic administration alone. Polymeric, lipid-based, biomimetic, and inorganic nanoplatforms demonstrated enhanced brain delivery and antitumor efficacy when combined with ultrasound-mediated opening of the BBB. Critical translational barriers identified included interspecies differences in BBB physiology, the “last-micron” intratumoral delivery challenge, manufacturing scalability, inconsistent reporting standards, and uncertainties regarding long-term neurotoxicity. Overall confidence in the evidence was rated moderate for preclinical outcomes (due to heterogeneity and risk of bias) and low for clinical outcomes (due to small sample sizes and lack of controlled trials). Limitations The available evidence was dominated by heterogeneous preclinical studies with variable methodologies and outcome measures. Direct head-to-head comparisons between combination therapies and monotherapies were limited, precluding quantitative meta-analysis. Publication bias and incomplete reporting may have led to an overestimation of therapeutic efficacy. The review's processes themselves were limited by the lack of a registered protocol and the exclusion of non-English studies. Conclusions The SDH framework provides a cohesive translational roadmap that bridges biomimetic nanomedicine design with externally controlled modulation of the BBB. The convergence of nanocarrier engineering and MRgFUS represents a promising strategy to overcome BBB-associated barriers to GBM therapy. Future progress will require standardized reporting practices, rigorous long-term safety assessment, adaptive theranostic platforms, and artificial intelligence-driven treatment personalization to facilitate clinical translation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ultrasound and Hyperthermia Applications · Nanoparticle-Based Drug Delivery · Glioma Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Therapeutic and diagnostic implications of exosomes as natural nanoparticles: a new paradigm in brain cancer disease management10.3389/fmed.2025.1599392 ↗
2. Characteristics of the blood–brain barrier in pediatric brain tumors10.3389/fped.2025.1646641 ↗
3. Diagnostics of brain tumor in the early stage: current status and future perspectives10.1039/D4BM01503G ↗
4. Nanoparticle-based delivery systems for targeted therapy in brain tumors: progress, challenges and perspectives10.3892/ijo.2025.5789 ↗
5. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy10.7150/thno.69682 ↗
6. The blood–brain barrier: structure, regulation, and drug delivery
7. Overcoming the blood-brain barrier. Challenges and tricks for CNS drug delivery10.3390/scipharm87010006 ↗
8. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
9. Nanotherapeutic strategies for overcoming the blood–brain barrier: applications in disease modeling and drug delivery10.1021/acsomega.5c02206 ↗
10. Recent advances of engineering cell membranes for nanomedicine delivery across the blood–brain barrier10.1186/s12951-025-03572-y ↗
11. Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma10.1038/s43246-024-00721-y ↗
12. Straehla
13. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers10.2217/nnm-2019-0367 ↗
14. Nanoparticle strategies to improve the delivery of anticancer drugs across the blood–brain barrier to treat brain tumors10.3390/pharmaceutics15071804 ↗
15. Overcoming blood-brain barrier by HER2-targeted nanosystem to suppress glioblastoma cell migration, invasion and tumor growth10.1039/C7TB02677C ↗
16. Nose-to-brain drug delivery: challenges and progress towards brain targeting in the treatment of neurological disorders
17. Nose-to-brain delivery of nanotherapeutics: transport mechanisms and applications10.1002/wnan.1956 ↗
18. Living cells and cell-derived vesicles: a trojan horse technique for brain delivery10.3390/pharmaceutics15041257 ↗
19. Biomimetic nanodelivery via cell membranes10.1002/adma.202402445 ↗
20. AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model10.15252/emmm.201809824 ↗
21. Understanding AAV vector immunogenicity: from particle to patient10.7150/thno.89380 ↗
22. Convection-enhanced drug delivery for glioblastoma: a review10.1007/s11060-020-03408-9 ↗
23. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial10.1016/S1470-2045(18)30322-X ↗
24. Focused ultrasound-mediated blood-brain barrier opening combined with magnetic targeting cytomembrane based biomimetic microbubbles for glioblastoma therapy10.1186/s12951-023-02074-z ↗
25. Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies10.1186/s12951-025-03352-8 ↗
26. Advancements in using polymeric nanoparticles for blood-brain barrier penetration in neurological disorders10.1021/acsabm.4c01956 ↗
27. Advances in blood–brain barrier-crossing nanomedicine for anti-glioma10.1186/s12645-023-00211-9 ↗
28. Stimuli-Responsive multifunctional nanomedicine for enhanced glioblastoma chemotherapy augments multistage blood-to-brain trafficking and tumor targeting10.1002/smll.202300029 ↗
29. Nanocarrier-engineered therapeutics for Glioblastoma: challenges and strategies for overcoming the blood-brain barrier
30. Strategies for delivering therapeutics across the blood–brain barrier10.1038/s41573-021-00139-y ↗
31. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics10.1039/C8CS00805A ↗
32. Cutting-edge advances in modeling the blood–brain barrier and tools for its reversible permeabilization for enhanced drug delivery into the brain10.1186/s13578-023-01079-3 ↗
33. Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release10.1002/advs.202004025 ↗
34. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB)10.3109/02652048.2012.692491 ↗
35. Drug transport across the blood-brain barrier10.1038/jcbfm.2012.126 ↗
36. Beyond the walls of troy: a scoping review on pharmacological strategies to enhance drug delivery across the blood–brain barrier and blood–tumor barrier10.3390/ijms26157050 ↗
37. The barrier and interface mechanisms of the brain barrier, and brain drug delivery10.1016/j.brainresbull.2022.09.017 ↗
38. Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood–brain barrier permeability
39. Receptor ligand-free mesoporous Silica nanoparticles: a streamlined strategy for targeted drug delivery across the blood-brain barrier10.1021/acsnano.3c08993 ↗
40. Cation-Free siRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy
41. Breaching the blood–brain tumor barrier for tumor therapy10.3390/cancers13102391 ↗
42. Sequential targeting in crosslinking nanotheranostics for tackling the multibarriers of brain tumors
43. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?10.1016/j.drudis.2008.09.005 ↗
44. Overcoming the blood–brain barrier: successes and challenges in developing nanoparticle-mediated drug delivery systems for the treatment of brain tumours10.2147/IJN.S231479 ↗
45. Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model10.1186/s12645-021-00084-w ↗
46. Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells10.7717/peerj.15571 ↗
47. Highly efficacious and specific anti-glioma chemotherapy by tandem nanomicelles co-functionalized with brain tumor-targeting and cell-penetrating peptides10.1016/j.jconrel.2018.03.025 ↗
48. Combinatorial therapeutic strategies for enhanced delivery of therapeutics to brain cancer cells through nanocarriers: current trends and future perspectives10.1080/10717544.2022.2069881 ↗
49. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles10.1038/s41598-020-68017-y ↗
50. Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound10.1016/j.nano.2018.01.021 ↗
51. Multifunctional fluoropolymer-engineered magnetic nanoparticles to facilitate blood-brain barrier penetration and effective gene silencing in medulloblastoma10.1002/advs.202401340 ↗
52. A biomimetic drug delivery System by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy10.1021/acs.nanolett.0c04753 ↗
53. Inducing a transient increase in blood-brain barrier permeability for improved liposomal drug therapy of glioblastoma multiforme10.1021/acsnano.8b03785 ↗
54. NIR-II fluorescence and magnetic resonance imaging-guided efficient piezodynamic therapy of subcutaneous glioblastoma with a biomimetic nanoplatform containing defect-engineered piezoelectric shell and downconversion Nanocore10.1002/smll.202510697 ↗
55. iRGD modified chemo-immunotherapeutic nanoparticles for enhanced immunotherapy against glioblastoma10.1002/adfm.201800025 ↗
56. Immune checkpoint-blocking nanocages cross the blood-brain barrier and impede brain tumor growth10.1021/acsbiomaterials.3c01200 ↗
57. Development of curcumin-loaded zein nanoparticles for transport across the blood-brain barrier and inhibition of glioblastoma cell growth10.1039/D0BM01536A ↗
58. Plga nanoparticle-based formulations to cross the blood-brain barrier for drug delivery: from r&d to cgmp10.3390/pharmaceutics13040500 ↗
59. Advances in the repurposing and blood–brain barrier penetrance of drugs in pediatric brain tumors10.3390/cancers17030439 ↗
60. Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment10.1038/s41467-023-40579-1 ↗
61. Targeted regulation of blood-brain barrier for enhanced therapeutic efficiency of hypoxia-modifier nanoparticles and immune checkpoint blockade antibodies for glioblastoma10.1021/acsami.1c00347 ↗
62. Focused ultrasound-mediated blood-brain barrier opening increases delivery and efficacy of etoposide for glioblastoma treatment10.1016/j.ijrobp.2020.12.019 ↗
63. Advancements in the blood–brain barrier penetrating nanoplatforms for brain related disease diagnostics and therapeutic applications10.3390/polym12123055 ↗
64. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
65. Ultrasmall core-shell silica nanoparticles for precision drug delivery in a high-grade malignant brain tumor model10.1158/1078-0432.CCR-19-1834 ↗
66. Crossing the blood–brain barrier with molecularly imprinted polymeric nanocarriers: an emerging frontier in brain disease therapy
67. Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood-brain barrier: an overview10.1016/j.cis.2023.103008 ↗
68. Solid lipid nanoparticle encapsulated beta-carotene for targeted breast cancer therapy: network pharmacology, molecular docking, and in vitro evaluation
69. Blood-Brain Barrier- and blood-brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases10.1021/acsami.9b14046 ↗
70. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy10.1038/s41467-023-37872-4 ↗
71. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy10.1016/j.biomaterials.2021.120784 ↗
72. Genetically engineered IL12/CSF1R-Macrophage membrane-liposome hybrid nanovesicles for NIR-II fluorescence imaging-guided and membrane-targeted mild photothermal-immunotherapy of glioblastoma
73. Bright NIR-II emissive cyanine dye-loaded lipoprotein-mimicking nanoparticles for fluorescence imaging-guided and targeted NIR-II photothermal therapy of subcutaneous glioblastoma10.1186/s12951-024-03074-3 ↗
74. Ferritin-based photoimmunotherapeutic Trojan horse in situ vaccine for glioblastoma and brain metastases via meningeal lymphatic delivery
75. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy10.1039/D3NR01667F ↗
76. Lipid nanocarriers as precision delivery systems for brain tumors10.1021/acs.bioconjchem.5c00007 ↗
77. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier10.1039/D2TB01440H ↗
78. Functional nanomaterial strategies for targeted CNS drug delivery10.26599/NR.2025.94907836 ↗
79. Ultrahigh resistivity and low-loss Mo6+-doped Ni-Zn ferrites for high-frequency inductive and EMI suppression components10.1007/s10853-025-12121-9 ↗
80. Tailoring structural, optical and magnetic properties of Ti-doped Ba0.8Sr0.2Fe12O19 for advanced magnetic devices10.1016/j.jallcom.2025.183582 ↗
81. Effects of plasma parameters on increasing the purity of nitrogen atom encapsulated fullerene in an RF plasma10.1016/j.mseb.2012.08.008 ↗
82. Synthesis and Properties of Nitrogen Atom Encapsulated Fullerene10.14723/tmrsj.34.773 ↗
83. Nanotechnology meets oncology: nanomaterials in brain cancer research, diagnosis and therapy10.3390/ma12101588 ↗
84. Human iPSC-Derived blood-brain barrier models: valuable tools for preclinical drug discovery and development?10.1002/cpsc.122 ↗
85. Nanomedicine and immunotherapy: a step further towards precision medicine for glioblastoma10.3390/molecules25030490 ↗
86. Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations10.1186/s40001-025-02310-2 ↗
87. Development of polymeric nanoparticles for blood–brain barrier Transfer—Strategies and challenges
88. Low-intensity MR-guided focused ultrasound mediated disruption of the blood-brain barrier for intracranial metastatic diseases10.3389/fonc.2018.00338 ↗
89. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases10.1016/j.jconrel.2016.05.044 ↗
90. Physico-Chemical and biological evaluation of PLCL/SF nanofibers loaded with oregano essential oil10.3390/pharmaceutics11080386 ↗
91. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
92. Current strategies for brain drug delivery10.7150/thno.21254 ↗
93. Overcoming the blood-brain barrier for drug delivery to the brain10.1021/acsomega.5c00364 ↗
94. Mathematical modeling and simulation of molecular mass transfer across blood brain barrier in brain capillary10.1016/j.molliq.2020.113254 ↗
95. Therapeutic effect of cabazitaxel and blood-brain barrier opening in a patient-derived glioblastoma model10.7150/ntno.31479 ↗
96. Blood-Brain barrier opening in primary brain tumors with non-invasive MR-Guided focused ultrasound: a clinical safety and feasibility Study10.1038/s41598-018-36340-0 ↗
97. Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma10.1158/1078-0432.CCR-18-3643 ↗
98. Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial10.1016/S1470-2045(23)00112-2 ↗
99. Specifically breaking through the injured blood-brain barrier with tannic acid-based nanomedicine for ischemic stroke ischemia reperfusion treatment10.1002/EXP.20240388 ↗
100. BBB-on-a-Chip: microfluidic tools as an alternative to in vivo experiments for nanosafety studies